Equillium Inc
NASDAQ:EQ

Watchlist Manager
Equillium Inc Logo
Equillium Inc
NASDAQ:EQ
Watchlist
Price: 0.7549 USD -3.22% Market Closed
Market Cap: 26.7m USD

Equillium Inc
Net Change in Cash

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Equillium Inc
Net Change in Cash Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Change in Cash CAGR 3Y CAGR 5Y CAGR 10Y
Equillium Inc
NASDAQ:EQ
Net Change in Cash
-$18.9m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Abbvie Inc
NYSE:ABBV
Net Change in Cash
-$7.3B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-19%
Gilead Sciences Inc
NASDAQ:GILD
Net Change in Cash
$3.9B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
-7%
Amgen Inc
NASDAQ:AMGN
Net Change in Cash
$1B
CAGR 3-Years
-16%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
Net Change in Cash
-$5.8B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Net Change in Cash
-$248.8m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A

Equillium Inc
Glance View

Market Cap
26.7m USD
Industry
Biotechnology

Equillium, Inc. engages in the development of products for severe autoimmune and inflammatory, or immuno-inflammatory, disorders with high unmet medical need. The company is headquartered in La Jolla, California and currently employs 45 full-time employees. The company went IPO on 2018-10-12. The firm develops products to treat severe autoimmune and inflammatory disorders with unmet medical needs. The firm's initial product candidate, itolizumab (EQ001), is a clinical-stage, monoclonal antibody that selectively targets CD6, a co-stimulatory receptor differentially expressed on subsets of pro-inflammatory T cells. The firm's CD6 plays a central role in the modulation of effector T cell, or Teff cell, activity and trafficking. Activated Teff cells drive several immuno-inflammatory diseases across therapeutic areas including transplant science, systemic autoimmunity, pulmonary, neurologic, gastrointestinal, renal, vascular, ophthalmic and dermatologic disorders. The company also provides structured-domain peptides, including BNZ-1 and BNZ-2, entirely in-house from product discovery platform. These lead product candidates are multi-specific inhibitors that targets range of immuno-inflammatory indication.

EQ Intrinsic Value
0.847 USD
Undervaluation 11%
Intrinsic Value
Price

See Also

What is Equillium Inc's Net Change in Cash?
Net Change in Cash
-18.9m USD

Based on the financial report for Sep 30, 2024, Equillium Inc's Net Change in Cash amounts to -18.9m USD.

Back to Top